WallStSmart

Insmed Inc (INSM)vsLENZ Therapeutics Inc (LENZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 3365% more annual revenue ($606.42M vs $17.50M). LENZ leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

LENZ

Avoid

30

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

LENZ1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

LENZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$344.19M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : LENZ

The strongest argument for LENZ centers on Price/Book.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : LENZ

The primary concerns for LENZ are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while LENZ is a value play — different risk/reward profiles.

LENZ carries more volatility with a beta of 1.76 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

LENZ generates stronger free cash flow (-9M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

LENZ Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

LENZ Therapeutics Inc is an innovative biopharmaceutical company dedicated to developing breakthrough therapies for neurological disorders, addressing significant unmet medical needs in the central nervous system (CNS). Utilizing advanced research in drug formulation and delivery, LENZ aims to enhance patient outcomes through its proprietary technologies and a robust product pipeline. The company’s strategic partnerships and commitment to rigorous clinical research underscore its potential as a key player in the biopharmaceutical industry, positioning it for considerable growth and influence in the evolving healthcare landscape.

Want to dig deeper into these stocks?